Tissue factor pathway inhibitor-2 (TFPI-2), a member of the Kunitz-type serine proteinase inhibitor family, is a structural homologue of tissue factor pathway inhibitor (TFPI). The expression of TFPI-2 in tumors is inversely related to an increasing degree of malignancy, which may suggest a role for TFPI-2 in the maintenance of tumor stability and inhibition of the growth of neoplasms. TFPI-2 inhibits the tissue factor/factor VIIa (TF/ VIIa) complex and a wide variety of serine proteinases including plasmin, plasma kallikrein, factor XIa, trypsin, and chymotrypsin. Aberrant methylation of TFPI-2 promoter cytosinephosphorothioate-guanine (CpG) islands in human cancers and cancer cell lines was widely documented to be responsible for diminished expression of mRNA encoding TFPI-2 and decreased or inhibited synthesis of TFPI-2 protein during cancer progression. Furthermore, an aberrantly spliced variant of TFPI-2 mRNA (designated asTFPI-2) was detected, which represents an untranslated form of TFPI-2. The levels of asTFPI-2 were very low or undetectable in normal cells but markedly upregulated in neoplastic tissue. TFPI-2 functions in the maintenance of the stability of the tumor environment and inhibits invasiveness and growth of neoplasms, as well as metastases formation. TFPI-2 has also been shown to induce apoptosis and inhibit angiogenesis, which may contribute significantly to tumor growth inhibition. Restoration of TFPI-2 expression in tumor tissue inhibits invasion, tumor growth, and metastasis, which creates a novel possibility of cancer patient treatment. However, more information is still needed to define the precise role of TFPI-2 in human tumor biology.
the identity of TFPI-2 with previously described placental protein 5 (PP5). 6 Three types of TFPI-2 molecules (33, 31, and 27 kDa), resulting from differential glycosylation, were identified in the extracellular matrix of human dermal fibroblasts and human umbilical vein endothelial cells (HUVECs). [7] [8] [9] Despite the structural similarity of TFPI-2 and TFPI, TFPI-2 serves as a weak inhibitor of tissue factor/ factor VIIa (TF/VIIa) complex, in contrast with TFPI. [1] [2] [3] The dominant activity of TFPI-2 is directed at the inhibition of a wide variety of serine proteinases including plasmin, 3, 6, 10, 11 plasma kallikrein, 3 trypsin and chymotrypsin, 3, 6, 12 as well as factor XIa. 3 TFPI-2 failed to exhibit any inhibitory activity toward glandular kallikrein, urinary plasminogen activator, tissue plasminogen activator, human activated protein C, leukocyte elastase, and thrombin. 3, 11 The gene responsible for human TFPI-2 synthesis is localized on chromosome 7q22. 13 The human TFPI-2 gene spans 7 kb and consists of five exons and four introns.
14 The TFPI-2 gene promoter exhibits features typical of a housekeeping gene. 15 
LOCALIZATION OF TFPI-2 UNDER NORMAL CONDITIONS
TFPI-2 is synthesized in endothelial cells (ECs) of different blood vessels (venous, arterial, and capillaries) but predominately by the ECs of small blood vessels 16 and is abundantly secreted (60 to 90%) into the extracellular matrix (ECM). 16 Furthermore, expression of the gene encoding TFPI-2 was detected in human ciliary epithelium, 17 mature placenta, heart, liver, kidneys, and skeletal muscles. 12 TFPI-2 mRNA was also demonstrated in syncytiotrophoblasts, 18 whereas the product of the gene was found both in syncytiotrophoblast and cytotrophoblast. 19 TFPI-2 protein was also immunohistochemically detected in seminal vesicles, 20 colon, breast, pancreas, stomach, larynx, kidney, endometrium, and brain tissue. 21 The plasma concentration of TFPI-2 in men and nonpregnant women is very low (0.43 to 0.49 ng/mL). 19 Moreover, TFPI-2 is present in seminal plasma, 22 preovulatory follicular fluid, 23 and in the mucus of the uterus. 19 
TFPI-2 PRESENCE IN NEOPLASTIC TISSUES
Immunohistochemical studies have provided suggestive evidence that the expression of TFPI-2 decreases with an increasing degree of malignancy (in the case of breast, gastric, colon, pancreatic, renal, laryngeal, and endometrial cancer and glial neoplasms). 21 The highest levels of TFPI-2 mRNA and protein were detected in normal brain, with lesser amounts in low-grade gliomas and anaplastic astrocytomas. In glioblastomas, TFPI-2 was undetected. 24 An inverse correlation between TFPI-2 distribution and the degree of malignancy was also observed in choriocarcinoma 18 and fibrosarcoma cell lines. 25 In addition, in about one third of non-small cell lung cancers (NSCLCs), TFPI-2 gene expression is decreased 4-to 120-fold compared with normal lung tissue. 26, 27 Neither pancreatic cancer cell lines nor primary pancreatic ductal neoplasms revealed expression of TFPI-2 mRNA. 28 Interestingly, high expression of TFPI-2 was observed exclusively in lobular carcinoma of the breast, which is known to be associated with a much more favorable prognosis than ductal invasive breast carcinoma. 21 Moreover, as much as 90% of hepatocellular carcinomas were characterized by underexpression of TFPI-2.
29 Thus, there is ample evidence that TFPI-2 production is reduced or absent during tumor progression. However, little is known concerning the molecular underpinnings of this phenomenon. ).Several highly aggressive cancers delete the locus for the TFPI-2 gene in chromosome 7q region, which results in a complete lack of TFPI-2 protein expression in these cells. [33] [34] [35] In human choriocarcinoma cell line, the minimal TFPI-2 promoter was demonstrated to be located between -166 and -111 from the translation start site, and nuclear factor-1 (NF-1), nuclear factor-kappa B (NF-kB), and early growth response gene-1 (egr-1)/specificity protein 1 (Sp1) binding sites were crucial for TFPI-2 inducible expression. 15 The promoter region -313 to þ 1 is critical for minimal and inducible promoter activity of human TFPI-2 in glioma cells. 36 This region harbors sites for several transcription factors, including SP1, activiting enhancer-binding protein-1 (AP-1), NF-kB and NF-kB-like site, and lymphoid transcription factor-1 (Lyf-1). 37 Mutations at either of two AP-1 sites (-310 to -300 and -163 to 154), as well as either of two SP1 sites (-192 to 183 and -135 to 128), lead to reduced TFPI-2 activity. 37 Promoter polymorphism of various genes is frequently responsible for regulation of functions of particular proteins. 26 However, none of 90 NSCLC patients exhibited genetic variations in the TFPI-2 promoter region.
GENETIC AND EPIGENETIC BASIS

26
Of particular interest is epigenetic inactivation of TFPI-2 synthesis. Aberrant methylation of TFPI-2 promoter cytosine-phosphorothioate-guanine (CpG) islands in human cancers and cancer cell lines was widely documented to be responsible for diminished mRNA encoding TFPI-2 and decreased or abolished synthesis of TFPI-2 protein during cancer progression.
27-30,38-41
The finding was associated with increased cancer growth, invasion, and dissemination.
27-29,38-41 Such a mechanism of TFPI-2 gene silencing was demonstrated in melanoma cell lines (HMV-I, MeWo, and WM-115), as well as in 30% of metastatic tumors, but not in primary melanoma surgical specimens. 38 One third of NSCLC patients, particularly at stage III and IV of the disease, exhibited methylation of TFPI-2 gene promoter in cancer cells. 27 Approximately one half of NSCLC cases with silenced TFPI-2 gene were lymph nodes positive.
27
TFPI-2 methylation was observed in all cases of esophageal adenocarcinomas examined.
39 Aberrant methylation of TFPI-2 was also revealed in as many as 73% of pancreatic cancer xenografts and primary pancreatic adenocarcinomas. 28 The finding was more frequently detected in older patients. 28 Interestingly, TFPI-2 methylation in endoscopically aspirated pure pancreatic juice was observed in 60% of pancreatic cancer patients in contrast with 20% in patients with intraductal neoplasms or 5% in individuals with chronic pancreatitis.
41
The incidence of the aberrant methylation of TFPI-2 in the pure pancreatic juice reached 100% when liver metastases were present and was as high as 90% in patients who presented at stage IV of the disease. 41 Promoter methylation was also documented to be responsible for TFPI-2 gene silencing in SNB19 glioblastoma cell line. 40 The finding was observed in 80% of hepatocellular carcinoma cell lines and in 50% of human hepatocellular carcinomas. 29 Although methylation of the TFPI-2 gene promoter leads to its silencing, it does not seem to provide the sole explanation for this phenomenon. 42 Rao et al 42 raised the hypothesis that one or more components of pathways regulating TFPI-2 expression had also undergone methylation-associated silencing in cancer cells. In this context, recent observations on the extracellular signal-regulated kinase family (ERK)/mitogen-activated protein kinase (MAPK) pathway mediation of the TFPI-2 promoter activity is of particular interest. 43 It has also been reported that TFPI-2 expression is downregulated in cells harboring activated ras oncogenes. 25 The Ras/Raf/mitogen-activity protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) signaling cascade regulates cell proliferation and differentiation. 44 Activation of components of the latter pathway, specifically oncogenic Ras and constitutively activated ERKs, are frequent findings in various human malignancies. [45] [46] [47] A novel mechanism, by which tumor cells circumvent the effects of TFPI-2, was recently discovered. 48 Specifically, an aberrantly spliced variant of TFPI-2 mRNA derived from TFPI-2 pre-mRNA splicing at exon/intron boundaries, as well as at new sites within exons and introns (designated asTFPI-2), was detected. 48 This form of TFPI-2 mRNA is untranslated. 48 The levels of asTFPI-2 were very low or negligible in normal cells but markedly upregulated in neoplastic tissue and in several cancer cell lines. 48 Based on the latter observation, it is conceivable that quantification of asTFPI-2 mRNA levels could be a marker of tumor progression.
Another facet of TFPI-2 regulation derives from its cleavage by other tumor environment components. Recently, an extracellular metalloproteinase, ADAMTS1, was shown to modify the binding properties of TFPI-2 that alter the extracellular location of the protein and disrupt its function. 49 It is particularly noteworthy that ADAMTS1 is expressed in human malignant tumors and plays a significant role in structural remodeling facilitating cancer invasion processes. 50 TFPI-2 gene is becoming increasingly recognized as a tumor suppressor gene. Marked downregulation of TFPI-2 expression is associated with increasing malignancy. 21, 24 However, this observation raises an important question regarding its biological relevance in aggressive tumors.
THE ROLE OF TFPI-2 IN MALIGNANCY
TFPI-2, an ECM-derived inhibitor, may function in the maintenance of the stability of the tumor environment and inhibit the growth of neoplasms. It has been shown to suppress invasion of choriocarcinoma tumor cells both in vitro and in vivo. 51 Similarly, TFPI-2 decreases invasion of human lung cancer A549cell line, 52 glioblastoma SNB19 cell line, 24, 53 fibrosarcoma HT-1080 cell line, 54 prostate cancer LNCaP cell line, 55 and amelanotic melanoma C-32 cell line. 56 The invasive potential of cancer derives from proteolytic activity driven by tumor cells, which results in ECM and basement membrane degradation. 57 In fact, TFPI-2 is thought to play a pivotal role in the regulation of plasmin-mediated ECM proteolysis. Downregulation of TFPI-2 protein concentration enhances cancer cell ability to degrade the ECM because TFPI-2 is a potent inhibitor of plasmin regardless of whether the enzyme is associated with the tumor cells or ECM.
3,58 TFPI-2 exerts inhibitory effect on plasmin-or trypsin-dependent activation of pro-matrix metalloproteinase (MMP)-1 and pro-MMP-3, which subsequently leads to diminished ECM degradation and decreased invasion of HT-1080 fibrosarcoma cell lines. 54, 59 In addition, it is conceivable that TFPI-2 may inhibit the plasmin-mediated release of proangiogenic molecules from the ECM components. Moreover, TFPI-2 has been demonstrated to inhibit MMP-2 formation in HT-1080 fibrosarcoma cell line 25 and to directly inhibit MMP-1, MMP-13, MMP-2, and MMP-9 in experimental models. 60 However, recently performed studies revealed that native TFPI-2 failed to form complexes with MMP-2, MMP-9, and MMP-1. 61 TFPI-2 also failed to inhibit the proteolytic activity of MMP-1 toward triple-helical collagen. 61 Experimental
TFPI-2 ROLE IN CANCER/SIERKO ET AL
studies focused on the effect of restoration of TFPI-2 revealed inhibition of invasion and tumor growth of several cancer lines.
28,62,63
A unique characteristics of TFPI-2 were observed in human hepatocellular carcinoma cell line. 64 The serine proteinase inhibitor was demonstrated to promote invasion, an effect that was suggested to be a result of TFPI-2 binding to TF-VIIa complex on cancer cells. 64 It is not obvious if this phenomenon represents the mechanism by which TFPI-2 exerts its activity in vivo because the results of another study revealed that hypermethylation of its gene promoter was detected in as many as 50% of human hepatocellular carcinomas, and ectopic overexpression of TFPI-2 markedly reduced the proliferation and invasiveness of hepatocellular carcinoma cells. 29 Significantly higher amounts of TFPI-2 gene promoter hypermethylation occurs in metastatic disease, in relation to its expression in localized cancer, 38, 41 suggesting that silencing of the TFPI-2 gene is involved in the process of metastases formation.
Tumor growth depends on the balance between the ratio of proliferation of cancer cells and their apoptosis. Recently, the role of TFPI-2 in the induction of apoptosis was described. 65, 66 Highly invasive human glioblastoma cells either lack or contain undetectable amounts of TFPI-2, whereas normal brain tissue and low-grade glial tumors express this protein abundantly. 21, 24 An increase in apoptosis was shown in aTFPI-2-positive multiforme glioblastoma cell line (SNB-19) and in low-grade glioma cell line (Hs683). 65 Restoration of TFPI-2 in human glioblastoma cell line (U-251) activates both intrinsic and extrinsic caspasemediated, proapoptotic signaling pathways and induces apoptosis. 66 It is thoroughly documented that activation of blood coagulation contributes to local progression of cancer and facilitates metastatic spread as well. [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] Tissue factor plays a key role in the initiation of coagulation activation in malignancy. 62, 82 The presence of TF was observed in loco in many tumors and resulted in increased invasiveness and higher rate of metastases formation. [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] The essential role in TF/VIIa inactivation is played by TFPI.
1,2 Another inhibitor of TFdependent pathway of blood coagulation is TFPI-2. It may inhibit tumor growth via interfering with TF activity. However, data on the influence of TFPI-2 on cancer biology by such a mechanism are scanty and will require additional studies. Nonetheless, it seems that there exists a regulatory self-restricting mechanism that, to some extent, counteracts TF influence on cancer progression. Namely, TF activity leads to thrombin generation, which upregulates TFPI-2 synthesis. 85 In this way, thrombin may contribute to suppression of the extrinsic pathway of blood coagulation and subsequently facilitate the maintenance of ECM and may attenuate TF-mediated impact on cancer progression.
The process of angiogenesis is a rate-limiting step in cancer progression. 85 Several studies highlight the role of TFPI-2 in the regulation of new blood vessel formation. In this regard, TFPI-2 was shown to inhibit angiogenesis in experimental models. 86, 87 The inhibitor is synthesized by ECs, particularly small blood vessels, and secreted abundantly into the ECM. 16 It may facilitate the maintenance of integrity of ECM and basement membrane of small blood vessels, thus preventing initiation of angiogenesis. Moreover, TFPI-2 plays a role in EC adhesion as anti-TFPI-2 IgG treatment of ECs leads to their detachment from the ECM. 16 Of interest, TFPI-2 in ECs is upregulated by the essential proangiogenic growth factor vascular endothelial growth factor (VEGF), which suppress proliferation of ECs. 88 This may represent the mechanism for negative-feedback regulation of VEGF activity.
Several highly aggressive neoplasms (melanoma as well as breast, lung, prostate, and ovarian cancer) develop a vessel-like network formed by cancer cells themselves; the process known as vasculogenic mimicry. [89] [90] [91] [92] [93] [94] [95] The structures play a role in sustained blood supply of the nascent tumor, and their formation was correlated with tumor progression. [89] [90] [91] [92] [93] [94] [95] In experimental melanoma, TFPI-2 was demonstrated to strongly contribute to vasculogenic mimicry plasticity. 96 The presence of TFPI-2 was demonstrated in tumor-infiltrating macrophages in gastric and renal carcinomas. 21 Cancer cells are able to synthesize and release several different cytokines that exert multidirectional influences on normal host cells 97 and inflammatory mediators, such as tumor necrosis factor-a (TNF-a), endotoxin, and phorbol esters, which stimulate synthesis and secretion of TFPI-2 by HUVECs. 9 The precise role of TFPI-2 localized in tumor-associated macrophages in cancer biology is still unknown.
On the basis of gene profiling and protein detection, it is tempting to speculate that TFPI-2 expression is attenuated during cancer progression, which facilitates invasion, tumor growth, angiogenesis, as well as metastases formation. Restoration of TFPI-2 in the tumor tissue inhibits the above-mentioned processes suggesting a novel therapeutic target for the treatment of cancer patients. However, additional information on the precise role of TFPI-2 in the tumor biology of particular types of human cancer is needed to design therapeutic options based on TFPI-2 structure and function. 
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